シャイア：製薬企業分析レポート

Abstract

Shire is a leading specialty pharmaceutical company traditionally focused on the treatment of attention deficit hyperactivity disorder (ADHD) and gastrointestinal disorders. In 2005, Shire completed the acquisition of Transkaryotic Therapies, broadening the company' s focus into the treatment of genetic and renal diseases. In 2007, Shire purchased New River Pharmaceuticals leading to a significant expansion of Shire' s ADHD product portfolio and pipeline. The company' s headquarters are based in the UK, however, during its 20 years of operation, Shire has established a significant presence throughout Europe and in the US.

In the last five years, Shire has spent over US$8 billion on acquisitions which have seen the company considerably expand its global presence and areas of interest. Most importantly, these acquisitions have added four key products to a portfolio that was becoming dated and facing threats to its intellectual property. The addition of Vyvanse (from New River Pharmaceuticals) will help further cement the company' s position as a leader in the treatment of attention deficit hyperactivity disorder (ADHD; traditionally Shire' s strongest field). Meanwhile, the additions of Replagal and Elaprase (both from Transkaryotic Therapeutics) have expanded Shire' s specialty centred business into the treatment of genetic diseases. Furthermore, Dynepo (also from TKT) has recently been launched and sees Shire enter the field of renal diseases.

During 2006, Shire reached a key settlement with Barr Pharmaceuticals. The two companies had been involved in patent litigation over Adderall XR, Shire' s top-selling product, which has patent protection until 2019. The agreement between the two companies allows Barr to launch its generic Adderall XR product ten years prior to patent expiry, however, it should prevent further patent challenges and limit generic competition until 2019. A key component of this agreement was the granting of a licence to Shire to begin developing Duramed Pharmaceuticals' (a subsidiary of Barr) new oral contraceptive, Seasonique, as well as five other products, which utilise Duramed' s transvaginal ring technology. With this licence, Shire could begin to move into yet another new key area of interest, women' s health, further expanding what was previously a very limited product portfolio.

This new strategic analysis report Shire: Pipeline · Products · Performance · Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. 4D Pharma reports are updated with the latest data on a continuing basis and the full report is released quarterly. Once a year the report undergoes a major review in line with the company' s year end. Buyers of the print/pdf editions will receive the latest version and quarterly updated reports for a year. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Table of Contents

• Latest Results

EXECUTIVE SUMMARY

• Introduction
• Current Financial Position
  • Company Performance
  • Business Segment Performance
  • Geographic Segment Performance
  • Total Assets by Geographical Area
• Company Strategy
  • Mergers, Acquisitions and Divestitures
    • Acquisitions
    • Divestitures
  • Key Agreements
• Product Performance Forecasts
  • Discontinued Products
• Pipeline Analysis
• Conclusions/Outlook

THER APEUTIC ARE A FOCUS

R&D PIPELINE

CENTRAL NER VOUS SYSTEM

• Marketed Products
  • Adderall/Adderall XR
  • Daytrana
  • Reminyl
  • Vyvanse
  • Others
• R&D Projects
  • Intuniv
  • NRP290
  • SPD465
  • SPD493
• Growth Forecast

GASTROINTESTINAL

• Marketed Products
  • Pentasa
• Growth Forecast

HUMAN GENETIC THERAPIES

• Marketed Products
  • Replagal
  • Elaprase
• R&D Projects
  • GA-GCB
• Growth Forecast

RENAL

• Marketed Products
  • Dynepo
  • Others
• R&D Projects
• Growth Forecast

OTHERS

• Marketed Products
• R&D Projects
  • Juvista
  • NRP409

APPENDIX 1 - FINANCIAL PER FORMANCE

• Full Year Results 2006

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGRE MENTS

• Alba Therapeutics Corp
• Amicus Therapeutics Inc
• Avexa Ltd
• Barr Pharmaceuticals Inc
• Bristol-Myers Squibb
• Genzyme Corporation
• Giuliani farmaceutici/Cosmo Pharmaceutical SpA
• Impax Laboratories Inc
• Johnson & Johnson
• Noven Pharmaceuticals
• Paladin Labs
• Renovo Group plc
• Samaritan Pharmaceuticals

APPENDIX 4 - INFRASTRUCTURE

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIE S/JOINT VENTURES

APPENDIX 6 - PRODUCT INDEX

Index of Tables

• Principal Operating Results
• Sales By Business Area
• Operating Income By Business Area
• Total Assets by Business Area
• Sales By Geogrpahic Area
• Recent Product Approvals
• Major Therapeutic Areas And Sales
• Major CNS Products, 2006
• Major Gastrointestinal Products, 2006
• Major HGT Products, 2006
• Major Renal Products, 2006
• Other Products, 2006

Index of Charts

• R&D Expenditure and Capital Expenditure
• Sales By Business Area, 2006
• Operating Income by Business Area
• Sale By Geographic Area
• Top 10 Selling Product Sales (2001A-2011E)
• Top Selling Products, 2006
• Adderall XR Sales (2001A-2011E)
• Daytrana Sales (2001A-2011E)
• Reminyl Sales (2001A-2011E)
• Intuniv Sales (2008E-2012E)
• Pentasa Sales (2001A-2011E)
• Replagal Sales (2001A-2011E)
• Elaprase Sales (2001A-2011E)
• Dynepo Sales (2007E-2011E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity